ArticleAsian Pacific journal of cancer prevention : APJCP2026
Crosstalk between ZEB1 expression and CD163+ Tumor-Associated Macrophages in Muscle-Invasive Urothelial Carcinoma.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is an urgent need to investigate the molecular mechanisms underlying the invasion and metastasis of bladder cancer to develop more effective therapeutic strategies and thereby reduce tumor-related morbidity and mortality. This study aimed to evaluate the prognostic significance of ZEB1 expression in bladder carcinoma (BC) and its association with tumor-associated macrophages (TAMs) within the tumor microenvironment (TME).
methodsA retrospective analysis was conducted on 48 patients with muscle-invasive bladder carcinoma (MIBC) who underwent radical cystectomy. Immunohistochemical staining for ZEB1 and CD163 was performed, followed by statistical analysis to assess their association with various clinicopathological parameters, including survival outcomes.
resultsHigh ZEB1 expression was significantly correlated with lymphovascular invasion, tumor necrosis, advanced disease stage, and nodal metastasis. Furthermore, elevated ZEB1 expression was associated with significantly worse 3-year overall survival (OS) and disease-free survival (DFS). Similarly, a high density of CD163+TAMs within TME was associated with adverse clinicopathological parameters and poor survival outcomes. Notably, a strong positive correlation was observed between ZEB1 expression and the density of CD163+ TAMs within the TME of BC. Multivariate analysis identified ZEB1 expression as an independent predictor of recurrence and nodal metastasis.
conclusionElevated ZEB1 expression is strongly associated with poor prognosis in BC and closely correlated with an increased density of CD163+TAMs, further contributing to adverse outcomes. These findings highlight the potential of ZEB1 as a prognostic biomarker and underscore the therapeutic relevance of targeting TAMs in the management of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.